Amarin's stock price has been almost cut in half since FDA approved Vascepa on July 26. It's not unusual these days to see a drug company's shares fall immediately after an FDA approval. Amarin was an extreme case, exacerbated by the lingering uncertainty surrounding Vascepa's market exclusivity and management's inability to land a marketing partner or sell the company outright. But the national commercial launch of Vascepa today gives Amarin a chance to put all the negativity and doubt of the past six months behind it. Vascepa reduces high triglyceride levels in the blood without causing elevations of LDL-C -- the so-called "bad cholesterol." GlaxoSmithKline's (GSK) competing fish-oil pill...
0 Responses to Amarin Deserves Chance to Reset With Vascepa Commercial Launch